ADNP (Activity-Dependent Neuroprotective Protein) is a 1,102 amino acid multidomain protein that functions as a transcription factor, chromatin remodeler, and microtubule stabilizer. ADNP is essential for brain development and neuronal survival. The ADNP-derived octapeptide NAP (davunetide/NAPVSIPQ) represents one of the most potent neuroprotective peptides known, acting through microtubule stabilization via end-binding proteins. ADNP directly interacts with [tau](/proteins/tau) and protects against tauopathy, connecting it to [Alzheimer's disease](/diseases/alzheimers-disease) and related dementias.
...
ADNP Protein
Overview
ADNP (Activity-Dependent Neuroprotective Protein) is a 1,102 amino acid multidomain protein that functions as a transcription factor, chromatin remodeler, and microtubule stabilizer. ADNP is essential for brain development and neuronal survival. The ADNP-derived octapeptide NAP (davunetide/NAPVSIPQ) represents one of the most potent neuroprotective peptides known, acting through microtubule stabilization via end-binding proteins. ADNP directly interacts with [tau](/proteins/tau) and protects against tauopathy, connecting it to [Alzheimer's disease](/diseases/alzheimers-disease) and related dementias.
ADNP is a large, multidomain protein with several functional regions:
Domain Architecture
N-terminal region (aa 1–350): Contains the nuclear localization signal and transactivation domain. Interacts with the SWI/SNF chromatin remodeling complex
Nine zinc fingers (distributed throughout): Mediate DNA binding at specific regulatory elements. Include both C2H2 and C4-type zinc finger motifs
Homeobox domain (aa 466–525): A 60 amino acid helix-turn-helix motif conferring sequence-specific DNA binding. Recognizes a 5'-ATTA-3' core motif
PxVxL motif (aa 601–605): Binds the chromoshadow domain of heterochromatin protein 1 ([HP1/CBX5](/genes/cbx5)), recruiting the BAF chromatin remodeling complex
NAP motif (aa 354–361, NAPVSIPQ): The neuroprotective octapeptide derived from the SIP domain. Interacts with microtubule end-binding proteins EB1 and EB3
SH3 domain-binding region: Mediates direct interaction with [tau](/proteins/tau) and [FYN](/genes/fyn) kinase
SUMOylation: SUMO modification at Lys-809 modulates transcriptional activity
Proteolytic processing: ADNP can be cleaved to release bioactive fragments including the NAP peptide
Normal Function
Transcriptional Regulation
ADNP regulates expression of over 400 genes involved in neuronal development, axon guidance, and synaptic plasticity. Key targets include:
[BDNF](/genes/bdnf) and [NGF](/genes/ngf) — neurotrophic factor expression
[MAP2](/genes/map2) and [MAPT](/genes/mapt) — microtubule-associated proteins
[BCL2](/genes/bcl2) — anti-apoptotic signaling
[SLIT1](genes/SLIT1) and [ROBO1](genes/ROBO1) — axon guidance molecules
ADNP binds chromatin through its homeobox domain and recruits the BAF complex through HP1-PxVxL interaction, establishing an active chromatin state at target gene promoters.
Microtubule Dynamics
The NAP motif is critical for ADNP's cytoplasmic function:
NAP binds EB1 and EB3 at microtubule plus-ends, stabilizing the dynamic instability of growing microtubules
Promotes microtubule polymerization and prevents depolymerization induced by nocodazole or [tau](/proteins/tau) hyperphosphorylation
Facilitates microtubule invasion into [dendritic spines](/cell-types/dendritic-spines), promoting spine maturation and synaptic stability
Protects axonal transport by maintaining microtubule tracks for [kinesin](/proteins/kinesin-1-heavy-chain-protein) and [dynein](/genes/dync1h1) motors
Neuroprotective Signaling
ADNP protein is secreted from [astrocytes](/entities/astrocytes) and acts in a paracrine manner to protect [neurons](/entities/neurons):
Reduces oxidative stress through upregulation of antioxidant enzymes
Modulates [p53](/genes/tp53) activity to prevent excessive neuronal apoptosis
Tau Interaction
ADNP directly binds tau through its SH3 domain-binding region:
Competes with [FYN](/genes/fyn) kinase for tau binding at the postsynaptic density
Prevents tau-mediated excitotoxicity by blocking Fyn-tau-[NMDA receptor](/entities/nmda-receptor) complex formation
Protects against tau hyperphosphorylation and missorting
ADNP deficiency leads to pathological tau accumulation in the somatodendritic compartment
Role in Disease
Alzheimer's Disease
ADNP has a biphasic relationship with AD:
Early compensatory increase: ADNP expression rises in early AD (MCI/Braak I-II) as a neuroprotective response to [amyloid-beta](/proteins/amyloid-beta) and oxidative stress
Late-stage decline: In advanced AD (Braak V-VI), ADNP levels drop significantly in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex), correlating with tau pathology severity
Serum biomarker: Peripheral ADNP levels (in lymphocytes and serum) are reduced in MCI and AD, potentially serving as an early biomarker
Tauopathy: ADNP haploinsufficiency in mice produces progressive tauopathy with hyperphosphorylated tau, [TDP-43](/proteins/tdp-43-protein) pathology, and cognitive decline
Amyloid interaction: NAP peptide protects against amyloid-beta oligomer toxicity in hippocampal neurons
ADNP Syndrome (Helsmoortel-Van der Aa Syndrome)
De novo loss-of-function mutations in ADNP cause a neurodevelopmental syndrome featuring:
ADNP mutations produce a specific neuropathological pattern resembling FTLD-TDP with comorbid tauopathy, suggesting ADNP dysfunction may contribute to FTD-spectrum disorders.
Therapeutic Targeting
NAP/Davunetide
The ADNP-derived NAP peptide (NAPVSIPQ) is the most advanced therapeutic:
Mechanism: EB1/EB3 binding, microtubule stabilization, tau protection
Phase II MCI trial: Intranasal AL-108 improved memory in amnestic MCI patients
Phase II/III PSP trial: Did not meet primary endpoint in [PSP](/diseases/progressive-supranuclear-palsy) but showed trends in biomarker improvement
Combinatorial: NAP + SKIP (another ADNP-derived peptide) shows synergistic neuroprotection
CP201 Gene Therapy
AAV-mediated ADNP gene replacement is in preclinical development for ADNP syndrome, showing behavioral rescue in haploinsufficient mice.
[Bassan et al., Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide (1999) (1999)](https://doi.org/10.1046/j.1471-4159.1999.0721283.x)
[Oz et al., The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins (2014) (2014)](https://doi.org/10.1038/mp.2013.152)
[Ivashko-Pachima et al., Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments are reversed by NAP (2019) (2019)](https://doi.org/10.1038/s41380-019-0428-1)
[Unknown, Gozes I., The ADNP Syndrome and CP201 (NAP) Potential and Hope (2020) (2020)](https://doi.org/10.3389/fnins.2020.00225)
[Helsmoortel et al., A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP (2014) (2014)](https://doi.org/10.1038/ng.2899)
[Mandel et al., Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin (2007) (2007)](https://doi.org/10.1002/dvdy.21265)
[Grigg et al., Tauopathy in the young autistic brain: novel biomarker and therapeutic target (2020) (2020)](https://doi.org/10.1038/s41398-020-0751-4)